Straumann (OTCMKTS:SAUHF) Upgraded at Zacks Investment Research

Straumann (OTCMKTS:SAUHFGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, Zacks.com reports. The firm presently has a $141.00 price target on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 14.63% from the stock’s current price.

According to Zacks, “The Straumann Group is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately on thousand seven hundred ninety people worldwide and its products and services are available in more than sixty countries through its broad network of distribution subsidiaries and partners. “

Shares of OTCMKTS:SAUHF opened at $123.00 on Thursday. The company has a current ratio of 2.72, a quick ratio of 2.27 and a debt-to-equity ratio of 0.46. Straumann has a 12 month low of $104.00 and a 12 month high of $230.12. The firm’s 50-day moving average is $178.42 and its 200 day moving average is $180.91.

About Straumann (Get Rating)

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss.

Featured Articles

Get a free copy of the Zacks research report on Straumann (SAUHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Want More Great Investing Ideas?

Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.